Bright Minds Biosciences
DRUG
6 hedge funds and large institutions have $230K invested in Bright Minds Biosciences in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
10% more capital invested
Capital invested by funds: $208K → $230K (+$21.6K)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.13% less ownership
Funds ownership: 4.43% → 4.29% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.85K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$1.61K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$169 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$11.8K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$46 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $219K | +$1.61K | +1,428 | +0.8% |
|
|
2
National Bank of Canada
Montreal,
Quebec, Canada
| $5.8K | -$46 | -41 | -0.8% |
|
|
3
UBS Group
Zurich,
Switzerland
| $3.99K | +$3.85K | +3,407 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$169 | +150 | +29% |
|
|
APC
5
Aspire Private Capital
Cornelius,
North Carolina
| $117 | – | – | – |
|
6
BlackRock
New York
| $1 | – | – | – |
|
|
7
Jane Street
New York
| – | -$11.8K | -10,937 | Closed |
|
DRUG Hedge Fund Activity: Q3 2024 in Review
6 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q3 2024, worth a combined $230K — up 10% from $208K a quarter earlier.
Fund positioning in DRUG was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $3.85K. The largest seller was Jane Street, exiting entirely with an estimated $11.8K sold.
- 6 institutional investors held Bright Minds Biosciences (DRUG) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $230K of Bright Minds Biosciences stock for Q3 2024, up 10% quarter-over-quarter.
- 1 fund opened new Bright Minds Biosciences positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest Bright Minds Biosciences buyer in Q3 2024 was UBS Group, an estimated $3.85K added.
- The largest Bright Minds Biosciences seller in Q3 2024 was Jane Street, an estimated $11.8K sold.
Based on aggregated 13F filings for Q3 2024.